U.S. Capital Wealth Advisors LLC Has $9.34 Million Position in GSK PLC Sponsored ADR (NYSE:GSK)

U.S. Capital Wealth Advisors LLC boosted its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 10.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 240,971 shares of the pharmaceutical company's stock after acquiring an additional 23,648 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in GSK were worth $9,335,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GSK. FMR LLC increased its stake in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after acquiring an additional 23,814,104 shares during the period. Primecap Management Co. CA grew its stake in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after buying an additional 10,407,905 shares during the last quarter. Voloridge Investment Management LLC grew its stake in GSK by 1,360.4% during the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after buying an additional 2,016,795 shares during the last quarter. Bridgewater Associates LP grew its stake in GSK by 132.7% during the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock worth $76,017,000 after buying an additional 1,281,855 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in GSK during the fourth quarter worth about $36,665,000. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GSK. Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat.com, GSK has an average rating of "Hold" and an average price target of $37.38.

GSK Price Performance

Shares of GSK stock traded up $0.03 during trading hours on Monday, reaching $38.21. 3,865,816 shares of the company were exchanged, compared to its average volume of 4,934,908. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67. The stock's fifty day moving average is $39.00 and its two-hundred day moving average is $37.14. The company has a market cap of $78.23 billion, a price-to-earnings ratio of 19.70, a P/E/G ratio of 1.53 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The company had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the business earned $0.43 earnings per share. GSK's quarterly revenue was up 2.1% on a year-over-year basis. Sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.41%. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is currently 87.11%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.